Literature DB >> 8880134

In situ expression of interleukin-10 and interleukin-12 in active human cutaneous leishmaniasis.

P C Melby1, F Andrade-Narvaez, B J Darnell, G Valencia-Pacheco.   

Abstract

Th1-type cellular immune responses (interferon-gamma) play a critical role in protection against Leishmania spp. infection, whereas Th2-type cytokines (interleukin (IL)-4, IL-10) have a counter-protective effect. IL-12, a potent inducer of Th1-type cellular immune responses, may play a pivotal role in the development of a protective response. We found that IL-10 and IL-12 mRNAs were expressed in most lesions of individuals with active cutaneous leishmaniasis. The quantity of IL-12 mRNA was highly variable but correlated strongly with the level of interferon-gamma expression. IL-12 expression also paralleled the expression of IL-10, a potent in vitro suppressor of IL-12 and interferon-gamma production. The more chronic, non-healing lesions generally had higher levels of IL-12 mRNA indicating that the expression of this cytokine alone was not sufficient to induce healing. Although the in situ production of IL-10 did not appear to block IL-12 expression, IL-10 may still promote disease by direct suppression of macrophage activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880134     DOI: 10.1111/j.1574-695X.1996.tb00059.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  16 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Serum cytokines in patients with Legionella pneumonia: relative predominance of Th1-type cytokines.

Authors:  K Tateda; T Matsumoto; Y Ishii; N Furuya; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

3.  Resistance/susceptibility to Echinococcus multilocularis infection and cytokine profile in humans. I. Comparison of patients with progressive and abortive lesions.

Authors:  V Godot; S Harraga; I Beurton; M Deschaseaux; E Sarciron; B Gottstein; D A Vuitton
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

4.  Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis.

Authors:  L P Carvalho; S Passos; O Bacellar; M Lessa; R P Almeida; A Magalhães; W O Dutra; K J Gollob; P Machado; A Ribeiro de Jesus
Journal:  Parasite Immunol       Date:  2007-05       Impact factor: 2.280

5.  Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection.

Authors:  S Ajdary; M H Alimohammadian; M B Eslami; K Kemp; A Kharazmi
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

6.  In situ immunopathological changes in cutaneous leishmaniasis due to Leishmania donovani.

Authors:  N H Manamperi; S Oghumu; N Pathirana; M V C de Silva; W Abeyewickreme; A R Satoskar; N D Karunaweera
Journal:  Parasite Immunol       Date:  2017-03       Impact factor: 2.280

7.  Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani.

Authors:  P C Melby; Y Z Yang; J Cheng; W Zhao
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

8.  Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10.

Authors:  Y A Nedialkov; V L Motin; R R Brubaker
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

9.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

10.  Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors.

Authors:  Rajesh Kumar; Ram A Bumb; Poonam Salotra
Journal:  Immunology       Date:  2010-01-22       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.